SecurityCBOE / CBOE Holdings, Inc. (12503M108)
IndustrySecurity And Commodity Brokers, Dealers, Exchanges, And Services
Common Stock Shares Outstanding112,553,369 shares (as of 2018-03-31)
Total Insiders32
Total Directors19
Total Officers14

Stock Insider Trading (from SEC Form 4)

CBOE / CBOE Holdings, Inc. Insider Trades

CBOE Holdings, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

CBOE / CBOE Holdings, Inc. insiders include Moffic-Silver Joanne, RATTERMAN JOSEPH P, Dean Alan J, Harkins Bryan, Isaacson Christopher A, Parisi James E. Sommers Jill E., and Tilly Edward T, MARTIN R EDEN, Provost Edward L, SKINNER SAMUEL K, Schell Brian N, Deters John, Froetscher Janet P, Stone Carole E, PALMORE RODERICK A, PHILLIPS SUSAN M, REYNOLDS DAVID S, BRODSKY WILLIAM J, BORIS JAMES R, Goodman Jill R, Lowenthal Andrew, Sunshine Eugene S, Richter Michael L, Fitzpatrick Edward J., CONCANNON CHRISTOPHER R, Farrow William M III, Hemsley Mark S, Sexton John P, Mitchell Christopher, English Frank E. Jr., O'Connell Gerald T, .

Insider Roster

Insider Dir Off 10% Shares Owned
Isaacson Christopher A Executive VP, CIO
X 77,500
CONCANNON CHRISTOPHER R President and COO
X 152,526
Froetscher Janet P Director
X 19,169
Fitzpatrick Edward J. Director
X 8,537
Farrow William M III Director
X 3,874
English Frank E. Jr. Director
X 5,322
Sommers Jill E. Director
X 0
Parisi James E. Director
X 0
Sunshine Eugene S Director
X 19,169
Stone Carole E Director
X 15,349
Richter Michael L Director
X 23,289
RATTERMAN JOSEPH P Director
X 33,621
PALMORE RODERICK A Director
X 18,869
Goodman Jill R Director
X 11,322
Schell Brian N Executive VP, CFO & Treasurer
X 50,541
Deters John EVP, Corporate Strategy
X 3,538
Lowenthal Andrew EVP, Global Derivatives
X 12,657
Sexton John P EVP, GC and Corp Sec
X 29,826
Harkins Bryan EVP, Equities and FX
X 83,878
Hemsley Mark S Executive VP, President Europe
X 97,654
Moffic-Silver Joanne Former EVP, GC, and Corp Sec
X 82,561
Tilly Edward T Chairman and CEO, Director
X X 102,000
REYNOLDS DAVID S Chief Accounting Officer
X 5,376
Dean Alan J Former EVP, CFO & Treasurer
X 75,052
BORIS JAMES R Director
X 10,161
Mitchell Christopher Director
X 0
SKINNER SAMUEL K Director
X 18,061
O'Connell Gerald T Former Executive VP and CIO
X
Provost Edward L Former President & COO
X
BRODSKY WILLIAM J Director
X
PHILLIPS SUSAN M Director
X
MARTIN R EDEN Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-06-06 4 Isaacson Christopher A S X D 100.02 -8,720 77,500 7,751,550
2018-06-06 4 Isaacson Christopher A M X D 22.08 8,720 86,220
2018-05-30 4 CONCANNON CHRISTOPHER R P D 99.44 10,000 152,526 15,167,185
2018-05-18 4 Schell Brian N S D 108.30 -5,000 50,541 5,473,590
2018-05-17 4 Goodman Jill R A D 1,108 11,322
2018-05-17 4 PALMORE RODERICK A A D 1,108 18,869
2018-05-17 4 Parisi James E. A D 1,108 1,108
2018-05-17 4 RATTERMAN JOSEPH P A D 1,108 33,621
2018-05-17 4 Richter Michael L A D 1,108 23,289
2018-05-17 4 Sommers Jill E. A D 1,108 1,108
2018-05-17 4 Stone Carole E A D 1,108 15,349
2018-05-17 4 Sunshine Eugene S A D 1,108 19,169
2018-05-17 4 English Frank E. Jr. A D 1,108 5,322
2018-05-17 4 Farrow William M III A D 1,108 3,874
2018-05-17 4 Fitzpatrick Edward J. A D 1,108 8,537
2018-05-17 4 Froetscher Janet P A D 1,108 19,169
2018-05-15 4 Deters John F D 108.11 -173 3,538
2018-05-15 4 Deters John M D 108.11 590 3,711
2018-03-16 4 Lowenthal Andrew L D 119.73 28 12,657
2018-02-28 4 Moffic-Silver Joanne F D 112.01 -181 82,561
2018-02-28 4 Moffic-Silver Joanne M D 408 82,742
2018-02-28 4 Moffic-Silver Joanne F D 112.01 -1,801 82,334
2018-02-28 4 Moffic-Silver Joanne M D 4,064 84,135
2018-02-28 4 Moffic-Silver Joanne F D 112.01 -1,057 80,071
2018-02-28 4 Moffic-Silver Joanne M D 2,384 81,128
2018-02-28 4 Moffic-Silver Joanne F D 112.01 -586 78,744
2018-02-28 4 Moffic-Silver Joanne M D 1,322 79,330
2018-02-28 4 CONCANNON CHRISTOPHER R F D 112.01 -2,031 142,526
2018-02-28 4 CONCANNON CHRISTOPHER R M D 112.01 4,146 144,557
2018-02-28 4 Schell Brian N F D 112.01 -919 55,541
2018-02-28 4 Schell Brian N M D 112.01 2,073 56,460
2018-02-28 4 Isaacson Christopher A F D 112.01 -460 77,500
2018-02-28 4 Isaacson Christopher A M D 112.01 1,036 77,960
2018-02-28 4 Hemsley Mark S F D 112.01 -581 97,654
2018-02-28 4 Hemsley Mark S M D 112.01 1,235 98,235
2018-02-19 4 REYNOLDS DAVID S F D 111.45 -218 5,376
2018-02-19 4 REYNOLDS DAVID S F D 111.45 -218 5,376
2018-02-19 4 REYNOLDS DAVID S F D 111.45 -278 5,812
2018-02-19 4 REYNOLDS DAVID S F D 111.45 -309 6,090
2018-02-19 4 REYNOLDS DAVID S M D 111.45 741 6,399
2018-02-19 4 REYNOLDS DAVID S M D 111.45 741 6,399
2018-02-19 4 REYNOLDS DAVID S M D 111.45 965 4,917
2018-02-19 4 REYNOLDS DAVID S M D 111.45 904 3,952
2018-02-19 4 Moffic-Silver Joanne F D 111.45 -900 78,008
2018-02-19 4 Moffic-Silver Joanne F D 111.45 -529 78,908
2018-02-19 4 Moffic-Silver Joanne F D 111.45 -466 79,437
2018-02-19 4 Moffic-Silver Joanne F D 111.45 -387 79,903
2018-02-19 4 Moffic-Silver Joanne M D 111.45 2,031 80,290
2018-02-19 4 Moffic-Silver Joanne M D 111.45 1,192 78,259
2018-02-19 4 Moffic-Silver Joanne M D 111.45 1,322 77,067
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

China Steps Up Support To Growth

2018-07-20 seekingalpha
Interesting policy action was taken in emerging markets today - with only China daring to ease further.

Nasdaq (NDAQ) Posts Mixed Q2 Volumes, Revenues Per Contract

2018-07-10 zacks
Nasdaq, Inc. (NDAQ - Free Report) has reported mixed volumes for second-quarter 2018. While U.S. equity options volume increased 8% year over year to 417 million contracts, European options and futures volumes registered 21.9 million contracts, down 1.4% year over year. However, revenues per contract for U.S. equity options remained flat year over year at 15 cents, although the same for European options and futures expanded 12. (2-0)

Intercontinental Exchange (ICE) Posts Record Volumes in Q2

2018-07-09 zacks
Intercontinental Exchange, Inc. (ICE - Free Report) has grossed record average daily volume (ADV) for Agriculture and Metals, which increased 13% year over year. Volumes in the second quarter were driven by better numbers in all the months of the quarter. The exchange operator witnessed record Oil ADV, increasing 2% year over year. While Euribor ADV improved 21% year over year, Gilt ADV was 29% higher. (4-0)

Why Is Cboe Global (CBOE) Down 7.5% Since its Last Earnings Report?

2018-06-04 zacks
It has been about a month since the last earnings report for Cboe Global Markets, Inc. (CBOE - Free Report) . Shares have lost about 7.5% in that time frame. (27-0)

Cboe Global (CBOE) Beats on Q1 Earnings, Revises Guidance

2018-05-07 zacks
Cboe Global Markets, Inc.’s (CBOE - Free Report) first-quarter 2018 adjusted earnings of $1.38 per share beat the Zacks Consensus Estimate of $1.27 by 8.7%. Moreover, the bottom line improved nearly 47% year over year. (104-0)